CRDF - CIK 0001213037
The table below shows Cardiff Oncology, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$37.92M | -$37.69M | -$30.89M | -$33.82M | -$23.04M | -$16.32M |
| Capital expenditure | $44.00K | $80.00K | $582.00K | $1.01M | $205.00K | $211.00K |
| Investing cash flow | $1.34M | $13.73M | $36.20M | $38.15M | -$131.45M | -$211.00K |
| Dividends paid | - | - | - | - | - |
Cardiff Oncology, Inc. reported operating cash flow of -$37.92M for fiscal year 2025. That is down 0.6% from -$37.69M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$13.20M (FY 2018) to -$37.92M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $2.58M | $53.78M | $0.00 | $75.00K | $35.45M | $137.31M |